All In Biotech

Drug Trial Radar · NCT04052737

PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease

A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Mar 23, 2018

Primary completion

Dec 20, 2022

Study completion Jan 6, 2023

Sponsor

Lead sponsor
Pharmazz, Inc.Industry
Sponsor type
Industry
First posted
Aug 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicentric, randomized, double blind, placebo controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 therapy along with standard supportive care in subjects with mild to moderate Alzheimer's disease.

Conditions

  • Alzheimer Disease
  • Dementia

Interventions

  • Normal Saline along with standard treatmentDrug

    PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.

  • PMZ-1620 (sovateltide) along with standard treatmentDrug

    PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of PMZ-1620 related adverse eventsTime frame: 160 days
  2. Number of patients not receiving full treatment due to intolerance to PMZ-1620Time frame: 160 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Post Graduate Institute of Medical Education and Research

    Chandigarh, India

  • King George's Medical University

    Lucknow, India

  • Sanjay Gandhi Post Graduate Institute of Medical Sciences

    Lucknow, India

  • Seth GSMC & KEM Hospital

    Mumbai, India

  • All India Institute of Medical Sciences

    New Delhi, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.